tradingkey.logo

Bio-Techne Corp

TECH

50.240USD

-0.539-1.06%
收盤 04/25, 16:00美東報價延遲15分鐘
7.93B總市值
50.18本益比TTM

Bio-Techne Corp

50.240

-0.539-1.06%
關於 Bio-Techne Corp 公司
Bio-Techne Corporation 是一家全球生命科學公司,爲研究和臨牀診斷界提供工具和生物活性試劑。該公司的產品有助於對生物過程以及特定疾病的性質和進展進行科學研究。該公司與 Wilson Wolf 合作,正在開發專門針對 G-Rex 生物反應器的產品,例如培養基和細胞因子。其部門包括蛋白質科學和診斷與基因組學。蛋白質科學部門是生命科學研究、診斷和細胞及基因治療各個方面所用生物試劑的開發商和製造商。該部門還包括手動和自動蛋白質組學分析工具。診斷與基因組學部門開發和製造診斷產品,包括用於受監管診斷市場的控制品、校準器和診斷檢測、基於外泌體的分子診斷檢測和組織活檢分析。
公司簡介
公司代碼TECH
公司名稱Bio-Techne Corp
上市日期Feb 09, 1989
成立日期1981
CEOMr. Kim Kelderman
員工數量3100
證券類型Ordinary Share
年結日Feb 09
公司地址614 Mckinley Pl N E
城市MINNEAPOLIS
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編55413
電話16123798854
網址https://www.bio-techne.com/
公司代碼TECH
上市日期Feb 09, 1989
成立日期1981
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
48.20K
+3.13%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
44.86K
+3.37%
Dr. Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Ph.D.
Independent Director
Independent Director
44.56K
+3.39%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
37.51K
--
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
13.77K
+11.88%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
9.35K
+18.54%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
7.13K
+25.77%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
3.19K
+90.01%
Dr. Matthew F. Mcmanus
Dr. Matthew F. Mcmanus
President - Diagnostics and Genomics Segment
President - Diagnostics and Genomics Segment
2.98K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
2.14K
+215.00%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
48.20K
+3.13%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
44.86K
+3.37%
Dr. Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Ph.D.
Independent Director
Independent Director
44.56K
+3.39%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
37.51K
--
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
13.77K
+11.88%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
9.35K
+18.54%
收入明細
單位: USD更新時間: 4月6日 週日
單位: USD更新時間: 4月6日 週日
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Consumables
230.72M
77.67%
Instruments
30.87M
10.39%
Service
27.35M
9.21%
Royalty
8.10M
2.73%
地區USD
名稱
營收
佔比
United States
159.91M
53.83%
EMEA, excluding U.K
70.39M
23.70%
Greater China
24.75M
8.33%
APAC, excluding Greater China
19.01M
6.40%
United Kingdom
13.24M
4.46%
Rest of World
9.73M
3.27%
業務
地區
業務USD
名稱
營收
佔比
Consumables
230.72M
77.67%
Instruments
30.87M
10.39%
Service
27.35M
9.21%
Royalty
8.10M
2.73%
股東統計
更新時間: 2月21日 週五
更新時間: 2月21日 週五
持股股東
股東類型
持股股東
股東統計
佔比
The Vanguard Group, Inc.
11.72%
T. Rowe Price Associates, Inc.
6.60%
BlackRock Institutional Trust Company, N.A.
5.85%
State Street Global Advisors (US)
4.09%
Baron Capital Management, Inc.
2.62%
Other
69.12%
持股股東
股東統計
佔比
The Vanguard Group, Inc.
11.72%
T. Rowe Price Associates, Inc.
6.60%
BlackRock Institutional Trust Company, N.A.
5.85%
State Street Global Advisors (US)
4.09%
Baron Capital Management, Inc.
2.62%
Other
69.12%
股東類型
股東統計
佔比
Investment Advisor/Hedge Fund
47.40%
Investment Advisor
44.16%
Hedge Fund
2.25%
Bank and Trust
2.16%
Pension Fund
1.88%
Research Firm
1.54%
Sovereign Wealth Fund
1.27%
Individual Investor
1.04%
Insurance Company
0.23%
機構持股
更新時間: 1月20日 週一
更新時間: 1月20日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
1193
162.20M
102.60%
-2.87M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
2023Q2
1213
155.36M
98.68%
-4.04M
2023Q1
1206
153.08M
97.33%
-5.18M
2022Q4
1190
153.16M
97.57%
-6.72M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
18.52M
11.72%
+275.81K
+1.51%
Dec 31, 2024
T. Rowe Price Associates, Inc.
10.43M
6.6%
+1.23M
+13.34%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
9.25M
5.85%
+4.60K
+0.05%
Dec 31, 2024
State Street Global Advisors (US)
6.47M
4.09%
+76.69K
+1.20%
Dec 31, 2024
Baron Capital Management, Inc.
4.14M
2.62%
-308.56K
-6.94%
Dec 31, 2024
Geode Capital Management, L.L.C.
4.00M
2.53%
+98.66K
+2.53%
Dec 31, 2024
Neuberger Berman, LLC
3.58M
2.27%
+65.69K
+1.87%
Dec 31, 2024
D. F. Dent & Company, Inc.
3.20M
2.03%
-97.30K
-2.95%
Dec 31, 2024
Atlanta Capital Management Company, L.L.C.
2.95M
1.87%
-40.17K
-1.34%
Dec 31, 2024
Mairs and Power, Inc.
2.82M
1.78%
-24.98K
-0.88%
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
Global X Genomics & Biotechnology ETF
4.16%
Invesco Biotechnology & Genome ETF
2.26%
Tema Monopolies and Oligopolies ETF
1.9%
VanEck Biotech ETF
1.79%
Hilton Small-MidCap Opportunity ETF
1.77%
Thrivent Small-Mid Cap ESG ETF
1.75%
iShares Health Innovation Active ETF
1.72%
Neuberger Berman Small-Mid Cap ETF
1.49%
Invesco S&P 500 Equal Weight Health Care ETF
1.27%
American Century Mid Cap Growth Impact ETF
0.98%
查看更多
Global X Genomics & Biotechnology ETF
佔比4.16%
Invesco Biotechnology & Genome ETF
佔比2.26%
Tema Monopolies and Oligopolies ETF
佔比1.9%
VanEck Biotech ETF
佔比1.79%
Hilton Small-MidCap Opportunity ETF
佔比1.77%
Thrivent Small-Mid Cap ESG ETF
佔比1.75%
iShares Health Innovation Active ETF
佔比1.72%
Neuberger Berman Small-Mid Cap ETF
佔比1.49%
Invesco S&P 500 Equal Weight Health Care ETF
佔比1.27%
American Century Mid Cap Growth Impact ETF
佔比0.98%
分紅派息
近5年累計派現 249.41M 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Feb 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
May 03, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 26, 2023 going ex on May 12, 2023
May 15, 2023
May 26, 2023
May 12, 2023
Feb 02, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 27, 2023 going ex on Feb 10, 2023
Feb 13, 2023
Feb 27, 2023
Feb 10, 2023
Nov 01, 2022
TECH.NB Final Cash Dividend of gross USD 0.32 paid on Nov 28, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Nov 28, 2022
Nov 10, 2022
查看更多
拆合股
公告日期
類型
比率
Nov 01, 2022
Split
1>4
公告日期
類型
比率
Nov 01, 2022
Split
1>4
tradingkey.logo
tradingkey.logo
日內數據由路孚特(Refinitiv)提供,並受使用條款約束。歷史及當前收盤數據均由路孚特提供。所有報價均以當地交易所時間為準。美股報價的即時最後成交數據僅反映透過納斯達克報告的交易。日內數據延遲至少15分鐘或遵循交易所要求。
* 參考、分析和交易策略由提供商Trading Central提供,觀點基於分析師的獨立評估和判斷,未考慮投資者的投資目標和財務狀況。
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有